China Pharma Partnerships News Roundup September 2020

face
main_img

Recent news from the cross-border deals and partnerships being struck by Chinese pharmacos, including I-Mab’s USD 2 billion immuno-oncology collaboration with AbbVie, Jiangsu Hengrui’s latest deal with US biotech Dyadic, and Fosun Pharma’s role in the Pfizer/BioNTech COVID-19 vaccine.

 

AbbVie and Chinese biotech I-Mab Enter Into Global Strategic Partnership worth up to USD 2 billion for Differentiated Immuno-oncology Therapy

https://news.abbvie.com/news/press-releases/abbvie-and-i-mab-enter-into-global-strategic-partnership-for-differentiated-immuno-oncology-therapy.htm

AbbVie (NYSE: ABBV) and I-Mab (Nasdaq: IMAB) announced today that AbbVie and I-Mab have signed a broad, global collaboration agreement for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two partners have the potential to expand the collaboration to additional transformative therapies.

 

Bankrupt US nutritional supplements retailer GNC takes first step to sell to China’s Harbin Pharma

https://www.axios.com/china-pharmaceutical-bankruptcy-gnc-e0aaea47-8f8c-4faf-86c2-07996917593f.html

GNC Holdings, the Pittsburgh-based nutritional supplements retailer, received bankruptcy court approval to sell itself to China’s Harbin Pharma for $770 million, although the deal still faces US political pressures over how GNC customer data is protected.

 

Nasdaq-listed US biotech Dyadic in high profile collaboration with China’s pharma giant Jiangsu Hengrui Medicine for biologic drug development

https://www.proactiveinvestors.com/companies/news/929375/dyadic-in-high-profile-collaboration-with-chinas-pharma-giant-jiangsu-hengrui-medicine-for-biologic-drug-development-929375.html

Dyadic International Inc (NASDAQ:DYAI) announced a collaboration on Thursday with Jiangsu Hengrui Medicine Company Limited (SSE:600276) to channel Dyadic’s proprietary C1 gene expression system to develop selected Hengrui biologic drugs.

 

Coronavirus mRNA vaccine co-developed by a German Biotech company BioNTech, a Chinese pharmaceutical company Fosun Pharma and a US Pharmaceutical company Pfizer, could be available for mass global inoculations by the end of 2020 if approved

https://www.globaltimes.cn/content/1200844.shtml

The mRNA vaccine has entered late-stage clinical trials and could be available for mass inoculations in the winter if successful, Hui Aimin, President of Global R&D, and Chief Medical Officer of Fosun Pharma, told the Global Times on Saturday. BioNTech and Pfizer jointly announced in August that, if approved, up to 100 million doses of vaccine worldwide would be produced by the end of 2020 and approximately 1.3 billion doses by the end of 2021.

 

Israeli pharma company Raziel Announces China Market License Agreement with Fosun Pharma for medical aesthetics drug RZL 012

https://www.biospace.com/article/releases/raziel-announces-china-market-license-agreement-with-fosun-pharma-for-rzl-012/

Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market announces licensing of its disruptive technology, RZL-012, to Fosun Pharma for milestone payments of up to $74 million, based on development, regulatory and net sales achievements plus tiered royalties on future sales.

 

Croma Establishes New Joint Venture in China

https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/croma-establishes-new-joint-venture-in-china

Austria-based medical aesthetic products’ manufacturer Croma-Pharma GmbH (“Croma”) establishes new Joint Venture with China National Biotech Group Company Ltd. (“CNBG”) to market its premium Hyaluronic Acid Filler Princess® VOLUME and various additional aesthetic products of Croma in China and Hong Kong.

Add Your Comment


You must be logged in to post a comment.

Related Content

Latest Report